Clinical Trial Update: A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating BMS-986504 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in untreated metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• BMS-986504
• Gemzar (gemcitabine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2, Phase 3 | Status: RECRUITING